×
AllNewsImagesVideos Maps Books
Search tools

NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled

Sahm
NovoCure (NVCR) stock is on the move after the company published final data from its pivotal Phase 3 METIS trial. The results, presented at...
4 days ago

Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting

Business Wire
Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain...
1 week ago

Novocure’s Lunar eclipse | ApexOnco - Clinical Trials news and analysis

Oncology Pipeline
Novocure disclosed the Lunar-4 discontinuation in an SEC filing, saying it planned to use real-world evidence instead – a move that will...
1 month ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

Yahoo Finance
BAAR, Switzerland, August 20, 2025--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S....
1 month ago

Novocure earns Japanese approval for tumor-treating fields

MassDevice
Novocure (Nasdaq:NVCR) announced today that it received regulatory approval in Japan for its Optune Lua wearable device.
3 weeks ago

Novocure at Wells Fargo Conference: Expanding Cancer Treatment Horizons

Investing.com
Novocure at Wells Fargo Conference: Expanding Cancer Treatment Horizons ... On Thursday, 04 September 2025, Novocure Ltd (NASDAQ:NVCR) presented...
1 month ago

NovoCure Q2 Revenue Jumps 6 Percent

Nasdaq
GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus (GAAP).
2 months ago

Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases

Sahm
Novocure announced that final results from its Phase 3 METIS trial showed Tumor Treating Fields (TTFields) therapy combined with best...
5 days ago

Novocure Reports Second Quarter 2025 Financial Results

Yahoo Finance
Novocure Reports Second Quarter 2025 Financial Results · Total net revenues for the quarter were $158.8 million, an increase of 6% compared to...
2 months ago

Novocure to Report Third Quarter 2025 Financial Results

Business Wire
Novocure (NASDAQ: NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open...
1 week ago